+1 858-523-8231
Login | Register
menu
AA Blocks, Building Blocks, Catalysts, Inhibitors
Login | Register
941690-55-7,MFCD18782739
Catalog No.:AA01EO9G

941690-55-7 | MLE-4901

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
≥98%
in stock  
$98.00   $68.00
- +
5mg
≥98%
in stock  
$383.00   $268.00
- +
10mg
≥98%
in stock  
$573.00   $401.00
- +
50mg
≥98%
in stock  
$956.00   $669.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
Technical Information
Catalog Number:
AA01EO9G
Chemical Name:
MLE-4901
CAS Number:
941690-55-7
Molecular Formula:
C26H25N3O3S
Molecular Weight:
459.5600
MDL Number:
MFCD18782739
SMILES:
CC[C@@H](c1ccccc1)NC(=O)c1c(NS(=O)(=O)C)c(nc2c1cccc2)c1ccccc1
Properties
Computed Properties
 
Complexity:
740  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
1  
Heavy Atom Count:
33  
Hydrogen Bond Acceptor Count:
5  
Hydrogen Bond Donor Count:
2  
Rotatable Bond Count:
7  
XLogP3:
5.1  

Literature

Title: Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial.

Journal: Lancet (London, England) 20170506

Title: Neurokinin B Receptor Antagonism in Women With Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial.

Journal: The Journal of clinical endocrinology and metabolism 20161101

Title: Population Pharmacokinetic and Pharmacodynamic Modeling of AZD4901 and Simulation to Support Dose Selection for the Phase 2a Study.

Journal: Journal of clinical pharmacology 20160801

Title: The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study.

Journal: Journal of clinical psychopharmacology 20140401

Title: In vitro assessment of metabolic drug–drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies.

Journal: Xenobiotica; the fate of foreign compounds in biological systems 20101101

Title: Li Y, et al. In vitro assessment of metabolic drug–drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies. Xenobiotica. 2010 Nov;40(11):721-9.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
Submit
SDS
Related Products of 941690-55-7
Building Blocks
More >
Tags:941690-55-7 Molecular Formula|941690-55-7 MDL|941690-55-7 SMILES|941690-55-7 MLE-4901
Catalog No.: AA01EO9G
941690-55-7,MFCD18782739
941690-55-7 | MLE-4901
Pack Size： 1mg
Purity： ≥98%
in stock
$98.00 $68.00
Pack Size： 5mg
Purity： ≥98%
in stock
$383.00 $268.00
Pack Size： 10mg
Purity： ≥98%
in stock
$573.00 $401.00
Pack Size： 50mg
Purity： ≥98%
in stock
$956.00 $669.00
Quantity
- +
Add to Card
Order Now
bulk Quotation Request
Technical Information
Catalog Number: AA01EO9G
Chemical Name: MLE-4901
CAS Number: 941690-55-7
Molecular Formula: C26H25N3O3S
Molecular Weight: 459.5600
MDL Number: MFCD18782739
SMILES: CC[C@@H](c1ccccc1)NC(=O)c1c(NS(=O)(=O)C)c(nc2c1cccc2)c1ccccc1
Properties
Complexity: 740  
Covalently-Bonded Unit Count: 1  
Defined Atom Stereocenter Count: 1  
Heavy Atom Count: 33  
Hydrogen Bond Acceptor Count: 5  
Hydrogen Bond Donor Count: 2  
Rotatable Bond Count: 7  
XLogP3: 5.1  
Literature fold

Title: Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial.

Journal: Lancet (London, England)20170506

Title: Neurokinin B Receptor Antagonism in Women With Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial.

Journal: The Journal of clinical endocrinology and metabolism20161101

Title: Population Pharmacokinetic and Pharmacodynamic Modeling of AZD4901 and Simulation to Support Dose Selection for the Phase 2a Study.

Journal: Journal of clinical pharmacology20160801

Title: The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study.

Journal: Journal of clinical psychopharmacology20140401

Title: In vitro assessment of metabolic drug–drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies.

Journal: Xenobiotica; the fate of foreign compounds in biological systems20101101

Title: Li Y, et al. In vitro assessment of metabolic drug–drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies. Xenobiotica. 2010 Nov;40(11):721-9.

Related Products of of 941690-55-7
Building Blocks More >
259674-19-6
259674-19-6
TRPM8 Antagonist
AA01EOFN | MFCD31746884
1366000-58-9
1366000-58-9
Atrial Natriuretic Peptide (ANP) (1-28), human, porcine Acetate
AA01EOKG | MFCD00133110
86583-19-9
86583-19-9
3-Deazaadenosine hydrochloride
AA01EOQ6 | MFCD31729546
1243583-88-1
1243583-88-1
2-hydroxy-6-[(1Z)-2-[4-(pentyloxy)phenyl]ethenyl]-benzoicacid
AA01EOYX
96096-52-5
96096-52-5
N-methyl-N-(1-methylethyl)-1H-indole-3-ethanamine
AA01EP9B | MFCD09033203
1890250-14-2
1890250-14-2
N-[[1-(5-hydroxypentyl)-1H-indazol-3-yl]carbonyl]-L-valine,methylester
AA01EPHG
95130-23-7
95130-23-7
3-(cyclohexylamino)-2,3-dihydro-2-(phenylmethylene)-1H-inden-1-one,monohydrochloride
AA01EPMF | MFCD16875416
1452396-10-9
1452396-10-9
rel-(+)-3-[(2E,6E)-9-[(1R,3S)-3-(acetyloxy)-2,2-dimethyl-6-methylenecyclohexyl]-3,7-dimethyl-2,6-nonadien-1-yl]-4-hydroxy-6-methyl-2H-pyran-2-one
AA01EPTF
145176-92-7
145176-92-7
N-[(1S,2R,3E)-1-[(β-D-galactopyranosyloxy)methyl]-2-hydroxy-3-heptadecenyl]-octadecanamide-d35
AA01EQ29
941987-60-6
941987-60-6
N-(4-ethylphenyl)-N'-1H-indol-3-yl-urea
AA01EQ9V | MFCD08026581
Submit
© 2017 AA BLOCKS, INC. All rights reserved.